CHARACTERISTICS OF Dyslipidemia and the DURATION of rheumatoid arthritis IN WOMEN

Purposeis: to study the characteristics of dyslipidemia and its types depending on the duration of rheumatoid arthritis, to determine the most significant combination of risk factors for the development of atherosclerosis in women with rheumatoid arthritis (RA). Material and methods: 223 women with RA were examined; the mean age was 55.3 ± 6.8 years. The patients were divided into 2 groups, depending on the duration of RA:group 1 included the patients with early RA lasting less than a year ( n = 87) and group 2 - more than 1 year ( n = 136). The patients from the group 2 were older than the women from the group 1 (55.7 ± 2.9 and 49.6 ± 1.4 years, respectively) ( p < 0.01). The analysis of risk factors for cardiovascular disease (CVD), blood lipid profile and markers of chronic inflammation, RA activity (VAS, DAS28), subclinical atherosclerosis markers was made. Total cardiovascular risk assessment in patients with RA was performed with mSCORE scale. Results. Dyslipidemia in women with RA is associated with markers of inflammatory activity (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and it is characterized by the increased LDL, triglycerides (TG), atherogenic index (AI) and decreased HDL. The increased level of total blood cholesterol was found to have been always associated with the abnormal content of other components of the lipid profile. Atherogenic dyslipidemia in early RA (group 1) occurred in 1.2 times more frequently than in patients having RA more than a year (72 and 62 % respectively), which is associated with the immune-inflammatory activity ( p < 0,05). Having been evaluated by mSCORE scale the risks for CVD in the groups were very high and high in more than 50 % of cases ( p < 0.05). Conclusion Dyslipidemia was common in groups. The significant predictors for atherosclerosis in women with RA can be supposed to be early menopause, pregnancy pathology, sleep disorders, depression, hypertension, increased total cholesterol level, LDL, AI, TG decreased HDL, high activity according to DAS 28, increased erythrocyte sedimentation rate, prednisolone taking.

rheumatoid arthritis, female, markers of inflammation, dyslipidemia, peripheral atherosclerosis

1. Ревматология: клинические рекомендации, утвержденные АРР в 2013 г. Федеральные клинические рекомендации по «ревматологии» с дополнениями от 2011 г. [Электронный ресурс]. Режим доступа: http://rheumatolog.ru/experts/klinicheskie-rekomendacii.

2. Шостак Н.А. Атеросклероз и ишемическая болезнь сердца у больных ревматоидным артритом: руководство по неишемической кардиологии. М.: ГЭОТАР-Медиа, 2009. С. 52-57.

3. Van Dorum S., McColl G., Wicks I.P. Accelerated atherosclerosis. An extraarticularbfeature of rheumatoid arthritis // Arthritis Rheum. 2002. Vol. 46. P. 862-875.

4. Avina-Zubieta J.A. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: ameta-analysis of observational studies // Arthritis Rheum. 2008. Vol. 59, N 12. P. 1690-1697.

5. Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы в ревматологии // Науч.-практ. ревматология. 2004. № 4. С. 4-9.

6. Европейское руководство по профилактике сердечно-сосудистых заболеваний в клинической практике (Пересмотр 2016) // Рос. кардиол. журн. 2017. № 6 (146). С. 7-85.

7. Normohamed M., Dijkmans B. Dyslipidemia, statins and rheumatoid arthritis // Ann. Rheum. Dis. 2009. Vol. 68. Р. 453-455.

8. Новикова Д.С., Попкова Т.В., Насонов Е.Л. Снижение кардиоваскулярного риска при ревматоидном артрите: двойная польза статинов // Науч.-практ. ревматология. 2010. № 6. С. 61-71.

9. Meune C., Touze E., Тrinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systemicreview and meta analisis of cohort studies // Rheumatology. 2009. N 48 (10). P. 1309-1313.

10. Баженов А.Н., Маслянский А.Л., Колесова Е.П. и др. Возможности ранней диагностики атеросклеротического поражения сосудов при ревматических заболеваниях // Атеросклероз. 2013. Т. 9, № 2. С. 34-35.

11. Starodubova J.N., Osipova I.V., Sopotova I.V. Arterial hypertension and complications of cardiovascular diseases in patients with rheumatoid arthritis // Therapy. 2015. P. 324.

12. Ahmed H.M., Youssef M., Mosaad Y.M. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis // Clin. Rheumatol. 2010. Vol. 29, N 11. P. 1237-1243.

13. Choi E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions // Ann. Rheum. Dis. 2009. Vol. 68. Р. 460-469.

14. Национальные рекомендации по кардиоваскулярной профилактике. 2011 // Кардиоваскулярная терапия и профилактика. 2011. Т. 10, № 6. Прил. 2. С. 2-64.

15. Agca R., Heslinga S.C., Rollefstad S. et al. EULAR recommendation for CVD Risk Management in patients with R A and other formw of Inflammotory Joint disorders: 20152016 // Аnn. Rheum. Dis. 2016. Vol. 76, N 1. Р. 17-28.

16. Norgren L., Hiatt W.R., Dormandy J.A. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) // J. Vasc. Surg. 2007. Vol. 45. Р. 5-67.

17. Georgiadis A.N., Papavasiliou E.C., Lourida E.S. et al. Atherogenic lipid profile is a feture characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study // Arthritis Res. Ther. 2006. Vol. 8, N 3. Р. 82.

18. Semb A.G. et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study // Ann. Rheum. Dis. 2010. Vol. 69, N 11. Р. 1996-2001.

19. Hansson G.K., Hermansson A. The immune system in atherosclerosis // Nat. Immunol. 2011. Vol. 12. Р. 204-212.

20. Jamnitski A., Levels J.H., van den Oever I.A., Nurmohamed M.T. Highdensity lipoprotein profiling chages in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study // J. Rheumatol. 2013. Vol. 40. Р. 825-830.

21. Serelis J., Panagiotakos D.B., Mavrommati M. et al. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study // J. Rheumatol. 2011. Vol. 38. Р. 236-241.

22. Steptoe А., Kivimaki M. Stress and cardiovascular disease: an update on current knowledge // Ann. Rev. Public. Health. 2013. Vol. 34. Р.337-254.

23. Boers M. et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with RA // Fnn. Rheum. Dis. 2003. Vol. 62. Р. 842-845.

24. Chatterjee Adhikari M., Guin A., Chakraborty S. et al. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as avidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study // Semin. Arthritis. Rheum. 2012. Vol. 41, N 5. Р. 669-675.

25. Chung C.P., Oeser A., Raggi P. et al. Increased coronary- artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risc factors // Arthritis Rheum. 2005. Vol. 52, № 10. Р. 3045-3053.

26. Södergren A., Karp K., Boman K. et al. Atherosclerosis in early rheumatoid arthritis: very early endothelialactivation and rapid progression of intima mrdia thicknes // Arthritis. Res. Ther. 2011. Vol. 13, N 4. Р. 131.